Drug therapy: Thiazolidinediones

被引：1650
作者：
Yki-Jarvinen, H [1 ]
机构：
[1] Univ Helsinki, Dept Med, Div Diabet, Helsinki 00029, Finland
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2004年 / 351卷 / 11期
关键词：
D O I：
10.1056/NEJMra041001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1106 / 1118
页数：13
相关论文
共 118 条
[1]   Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation [J].
Adams, M ;
Montague, CT ;
Prins, JB ;
Holder, JC ;
Smith, SA ;
Sanders, L ;
Digby, JE ;
Sewter, CP ;
Lazar, MA ;
Chatterjee, VKK ;
O'Rahilly, S .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) :3149-3153
[2]   Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy [J].
Addy, CL ;
Gavrila, A ;
Tsiodras, S ;
Brodovicz, K ;
Karchmer, AW ;
Mantzoros, CS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (02) :627-636
[3]  
[Anonymous], N ENGL J MED
[4]   Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes [J].
Arioglu, E ;
Duncan-Morin, J ;
Sebring, N ;
Rother, KI ;
Gottlieb, N ;
Lieberman, J ;
Herion, D ;
Kleiner, DE ;
Reynolds, J ;
Premkumar, A ;
Sumner, AE ;
Hoofnagle, J ;
Reitman, ML ;
Taylor, SI .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (04) :263-274
[5]   Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity [J].
Arita, Y ;
Kihara, S ;
Ouchi, N ;
Takahashi, M ;
Maeda, K ;
Miyagawa, J ;
Hotta, K ;
Shimomura, I ;
Nakamura, T ;
Miyaoka, K ;
Kuriyama, H ;
Nishida, M ;
Yamashita, S ;
Okubo, K ;
Matsubara, K ;
Muraguchi, M ;
Ohmoto, Y ;
Funahashi, T ;
Matsuzawa, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (01) :79-83
[6]   Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study [J].
Aronoff, S ;
Rosenblatt, S ;
Braithwaite, S ;
Egan, JW ;
Mathisen, AL ;
Schneider, RL .
DIABETES CARE, 2000, 23 (11) :1605-1611
[7]   Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial [J].
Azziz, R ;
Ehrmann, D ;
Legro, RS ;
Whitcomb, RW ;
Hanley, R ;
Fereshetian, AG ;
O'Keefe, M ;
Ghazzi, MN .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (04) :1626-1632
[8]   Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients [J].
Bajaj, M ;
Suraamornkul, S ;
Piper, P ;
Hardies, LJ ;
Glass, L ;
Cersosimo, E ;
Pratipanawatr, T ;
Miyazaki, Y ;
Defronzo, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (01) :200-206
[9]   Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes [J].
Bajaj, M ;
Suraamornkul, S ;
Pratipanawatr, T ;
Hardies, LJ ;
Pratipanawatr, W ;
Glass, L ;
Cersosimo, E ;
Miyazaki, Y ;
DeFronzo, RA .
DIABETES, 2003, 52 (06) :1364-1370
[10]   Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis [J].
Barbier, O ;
Torra, IP ;
Duguay, Y ;
Blanquart, C ;
Fruchart, JC ;
Glineur, C ;
Staels, B .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (05) :717-726
12345678910